JPMorgan assumed coverage of Treace Medical (TMCI) with a Neutral rating and $8 price target While believers in the company’s Lapiplasty value proposition, the firm thinks Treace has more work to do to restore growth and investor confidence in the long-term outlook.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace announces first surgical cases utilizing SpeedPlate MicroQuad Implant
- Treace announces cases using RedPoint Intelliguide PSI with Adductoplasty
- Treace Medical announces Guy Guglielmino as chief commercial officer
- Treace Medical assumed with an Equal Weight at Morgan Stanley
- Treace Medical price target raised to $8 from $7 at Stifel